Fortress' Caelum subsidiary reports MTD for CAEL-101 in AL amyloidosis

The Caelum Biosciences Inc. subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) said data from a U.S. Phase Ia/Ib trial established 500 mg/m2 as the maximum tolerated dose (MTD), the primary endpoint, of

Read the full 314 word article

User Sign In